Metformin is a first-line drug in the treatment of type II diabetes, one of its effects is to activate AMPK indirectly to affect the treatment of diabetes (Agius et al., 2020; Zhang et al., 2020; Kaneto et al., 2021). This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.